Glanbia Plc · EURONEXT:GL9
Glanbia — Q3 2026 Earnings Presentation
11 slides from Glanbia's earnings presentation, Nov 4, 2026
Slide 1: Q3 2026 Interim Management Statement
Q3 2026 Interim Management Statement 04 November 2026 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
I M P O R T A N T N O T I C E This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both econ
Slide 3: Highlights
HIGHLIGHTS Q3 2026 Strong YTD Q3 performance with volume growth across all three segments PN LFL revenue1 +18.0% driven by strong growth in Optimum Nutrition (+25.8%) H&N LFL revenue1 +9.8% with strong volume growth driven by demand across end-use markets Continued momentum in DN with strong growth
Slide 4: Performance Nutrition (PN)
PERFORMANCE NUTRITION (PN) Strong year-to-date performance led by Optimum Nutrition Total revenue Q3 YTD1 +8.5% Volume +4.3% Price +13.7% Disposals (9.5%) • Q3 YTD LFL revenue2 +18.0% • Volume +4.3% driven by accelerating category growth, market share gains, new distribution and innovation • Pricing
Slide 5: Health & Nutrition (H&N)
H E A LT H & N U T R I T I O N ( H & N ) Continued strong volume growth momentum driven by demand in end-use markets Total revenue Q3 YTD1 +12.8% Volume +11.5% Price (1.7%) Acquisitions +3.0% • H&N LFL2 revenue +9.8% • Volume +11.5% driven by continued strong growth across core end- use markets of A
Slide 6: Dairy Nutrition (DN)
D A I RY N U T R I T I O N ( D N ) Strong performance through volume and pricing in Protein Solutions Total revenue Q3 YTD1 +2.1% Volume +1.4% Price +0.7% • LFL2 revenue +2.1% • Volume +1.4% driven by good demand for protein solutions and bioactives with demand for high-end whey proteins remaining r
Slide 7: Strong Balance Sheet
STRONG BALANCE SHEET DEBT CAPITAL SHAREHOLDER EXPENDITURE RETURNS Net Debt $704m FY26 capex expected to be €100m returned via share $100m – $110m buyback programme Total committed facilities of $1.3bn €102m returned in dividends 7 | Glanbia PLC Q3 2026 IMS Presentation
Slide 8: FY26 Outlook Upgraded
FY26 OUTLOOK UPGRADED PN H&N DN Revenue growth: +16-17% Revenue growth: +8-10% EBITDA in a range of EBITDA margin progression EBITDA margin: 17-19% $175-180m Adj. EPS1 growth 22% - 24% OCF Conversion 85%+ FY26 OUTLOOK AHEAD OF MEDIUM-TERM ALGORITHM 8 | Glanbia PLC Q3 2026 IMS Presentation 1 On a con
Slide 9: A Performance Driven Purpose Led Global Nutrition Company
A PERFORMANCE DRIVEN PURPOSE L E D G L O B A L N U T R I T I O N C O M PA N Y 9 | Glanbia PLC Q3 2026 IMS Presentation
Slide 10: Appendices
A APPENDICES 10 | Glanbia PLC Q3 2026 IMS Presentation
Slide 11: Quarterly Revenue Trends
Q U A R T E R LY R E V E N U E T R E N D S YTD 2026 results summary (pre-exceptional)) Revenue Progression YTD 2026 versus YTD 2025 Constant Currency Movement Acquisitions / Total Constant Volume Price Like-for-like (LFL) (disposals) Currency Performance Nutrition 4.3% 13.7% 18.0% (9.5%) 8.5% Health